Lack of Institutional Support May Drive Physician Reluctance to Address Addiction
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, July 24, 2024 -- Lack of institutional support is the most common reason for physicians to have reluctance to address substance use and addiction in their clinical practices, according to a review published online July 17 in JAMA Network Open.
Melinda Campopiano von Klimo, M.D., from JBS International Inc. in North Bethesda, Maryland, and colleagues conducted a systematic literature review to understand physician-reported reasons for reluctance to address substance use and addiction in their clinical practices through screening, treatment, harm reduction, or recovery support interventions.
Based upon 283 studies (66,732 physicians), the researchers found that alcohol, nicotine, and opioids were the most often studied substances, while screening and treatment were the most often studied interventions. Lack of institutional support (81.2 percent), knowledge (71.9 percent), skill (73.9 percent), and cognitive capacity (73.5 percent) were the most common reluctance reasons. Additionally, reimbursement concerns were also noted. These reasons varied by physician specialty, intervention type, and drug.
"These findings suggest effort should be directed at creating institutional environments that facilitate delivery of evidence-based addiction care while improving access to both education and training opportunities for physicians to practice necessary skills," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-25 01:15
Read more
- 'Dawson's Creek' Star James Van Der Beek Has Colon Cancer
- Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
- Kids' Injuries in Sports and at Home: When Is It Right to Seek Medical Attention?
- Reducing Sedentary Time, Increasing Standing Does Not Reduce BP
- Obesity-Linked Heart Deaths Nearly Tripled in U.S. Over Past Two Decades
- FDA Approves Orlynvah (sulopenem etzadroxil and probenecid) for the Treatment of Uncomplicated Urinary Tract Infections
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions